Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers. - Wikidata - wikimedia - TriplyDB

Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.

Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.

http://www.wikidata.org/entity/Q27853297

about

CIViC database Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers.Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts.miR-143-3p targeting of ITGA6 suppresses tumour growth and angiogenesis by downregulating PLGF expression via the PI3K/AKT pathway in gallbladder carcinoma.RET rearrangements are actionable alterations in breast cancer

P2860

dec61d342af81f0cde0c619e86f5245194e81af1

P248

Q27612411-4B7AF310-CA98-4899-A2E8-52EBF392F8E1 Q37565435-A1BA885C-0607-4515-B0FB-ED6D15C0AB50 Q37697034-8FF12390-3C6A-4845-9E36-4B8562C59878 Q50130129-A99E9EBC-36DD-4819-9526-46E0390196FF Q59136613-30F2D2D7-2610-4834-9D0B-9D4334230752

P2860

Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.

http://www.wikidata.org/entity/Q27853297

description

2016 nî lūn-bûn

@nan

2016 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.

@ast

Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.

@en

Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.

@nl

type

label

Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.

@ast

Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.

@en

Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.

@nl

prefLabel

Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.

@ast

Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.

@en

Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.

@nl

P1433

Q27853297-A0E9A098-865D-42A6-9F4E-872339EAF07D

P1476

Q27853297-26E97798-8AE5-420A-A48D-CD201C7C903D

P2093

Q27853297-152FF6B7-7B2F-46F7-8DFD-A5A26ABF5B8C

Q27853297-8FDB5F03-5368-4A22-8718-D0B30477121A

Q27853297-9A4A18C7-933A-48AA-BF59-4C68AD00DEAA

Q27853297-A2C13DBF-B2EA-4558-8125-FF38C4701CBF

Q27853297-A832C699-3063-4160-A98B-F551834BAB33

Q27853297-B4976307-EAEF-4AF8-87A4-43D1CB0B9BBD

Q27853297-D6FA484A-A220-4E9E-9C4F-FC544D7547CC

P2860

Q27853297-06821A08-5363-4913-A19E-8A9153BDD3EF

Q27853297-15A5AEE8-9DA2-45FE-AD07-80E46E8048AE

Q27853297-2A402407-D185-4A29-835D-817E05A67E5B

Q27853297-2ACC6F8E-25BB-4B98-9530-1F71D7C37693

Q27853297-39D2F20D-2332-48F1-BF8C-74A1F8B4DA9A

Q27853297-3D926315-C4AC-4AF2-BD63-B1053B28A328

Q27853297-40B20453-C0EC-482C-BB80-744F0FC5F9BD

Q27853297-486E8402-C99B-4E43-A36A-F4CA60AC4984

Q27853297-546D568F-BAF3-40D3-96F3-2F1DDC40D869

Q27853297-6BA6827F-4A7A-4EDF-AAFD-12B256A78C48

P304

Q27853297-A44CBE52-209F-4061-B356-5B84FFCCD8EF

P31

Q27853297-4F43D17F-C3AE-461E-93DC-22103542E6BF

P3181

Q27853297-3F198102-1881-4E10-8334-3F415B5ECBC3

P356

Q27853297-654A934E-7C7C-4711-B7D5-EBA056AF5263

P433

Q27853297-876BD0C5-FA11-40D4-BF89-12D7C9ADD7C2

P478

Q27853297-DDBDC4EC-D659-42A6-A663-2A930B76D7F8

P50

Q27853297-2B23236F-0748-4DAF-86C8-61AAC69843CA

Q27853297-8FCCEFE2-C100-493C-AB70-FE09234F6E91

Q27853297-92011FE6-D4E8-4031-A064-E44DF11F0CF2

Q27853297-C5E9EE2D-26DC-40CB-ADCB-DE109DFE508E

P577

Q27853297-C02F8D09-F9F0-4918-B8FE-A6DD679A8DC4

P698

Q27853297-A91082AB-90C5-4B5F-B891-5DFDF18EE6E0

P3181

P356

P1433

International Journal of Cancer

P1476

Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers

@en

P2093

Dalila Labiod

http://www.w3.org/2001/XMLSchema#string

Florian Bonin

http://www.w3.org/2001/XMLSchema#string

Jean-Luc Servely

http://www.w3.org/2001/XMLSchema#string

Ludmilla de Plater

http://www.w3.org/2001/XMLSchema#string

Rana Hatem

http://www.w3.org/2001/XMLSchema#string

Sophie Château-Joubert

http://www.w3.org/2001/XMLSchema#string

Véronique Dieras

http://www.w3.org/2001/XMLSchema#string

P2860

Comprehensive molecular portraits of human breast tumours

Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction

Vandetanib for the treatment of medullary thyroid cancer

MAPK-regulated transcription: a continuously variable gene switch?

A quantitative analysis of kinase inhibitor selectivity

Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings

Inhibiting aurora kinases reduces tumor growth and suppresses tumor recurrence after chemotherapy in patient-derived triple-negative breast cancer xenografts.

Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism.

Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.

Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy.

P304

2510-2521

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4757513

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/IJC.29974

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

138

http://www.w3.org/2001/XMLSchema#string

P50

Elisabetta Marangoni

P577

2016-01-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26686064

http://www.w3.org/2001/XMLSchema#string